CapsoVision Reports Increased Revenue and Widened Net Loss for Full Year 2025 Amidst Heavy R&D Investments
CV has more than doubled off its 52-week low of $3.434.
Summary
CapsoVision reported a 15% increase in full year 2025 revenue to $13.6 million, but net loss widened to $25.3 million due to increased operating expenses from R&D investments.
Key Events · Earnings and Guidance · CV
-
Full Year 2025 Financial Results
Revenue increased by 15% to $13.6 million, while gross profit rose 12% to $7.2 million. However, the company reported a net loss of $25.3 million, widening from $19.9 million in 2024.
-
Increased Operating Expenses
Operating expenses surged to $32.7 million for the full year, a $6.4 million increase, primarily due to significant investments in R&D for a new CMOS image sensor and clinical trial activities for AI technology and next-generation capsule development.
-
Product Development Milestones
The company submitted a 510(k) application to the FDA for its in-house developed AI-assisted module for CapsoCam Plus®, marking progress in enhancing capsule endoscopy solutions.
-
Liquidity Position
Cash and cash equivalents stood at $10.1 million as of December 31, 2025. The company recently closed a $14 million private placement on March 16, 2026, which was previously announced and provides additional capital.
Analysis · CV · Industrial Applications And Services
CapsoVision's latest earnings report reveals a mixed financial picture. While the company achieved notable revenue growth and made significant progress in product development, including an FDA submission for its AI-assisted module, it also experienced a substantial increase in operating expenses, leading to a widened net loss for the full year 2025. These increased expenses are primarily driven by investments in R&D for new technologies and clinical trials. The company's liquidity was bolstered by a recently completed $14 million private placement, which was previously disclosed, providing capital to support ongoing operations and development initiatives. Investors should monitor the company's ability to translate its R&D investments into profitable growth and manage its cash burn.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 28.9% of the 1666 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CV was trading at $7.38 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $352.7M. The 52-week trading range was $3.43 to $15.37. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.